Methylene Blue

Methylene blue is a synthetic dye first made in 1876 that became one of the earliest true pharmaceutical drugs. It is FDA-approved today, at a specific IV dose, to treat methemoglobinemia, a blood disorder that prevents red blood cells from carrying oxygen properly. In recent years it has also drawn attention in longevity and cognitive-enhancement communities as an off-label “nootropic” and mitochondrial-support compound, an entirely different use case with far less rigorous human evidence behind the doses being discussed.

Research snapshot

Peptide category	Small-molecule synthetic phenothiazine dye (not a peptide); FDA-approved drug repurposed off-label as a nootropic/mitochondrial-support compound
Primary research interest	Approved use: methemoglobinemia. Off-label interest: cognitive enhancement, mitochondrial support, longevity
Highest available evidence	Tier 1 for its approved indication (methemoglobinemia); considerably weaker (preliminary/mixed) for off-label nootropic/longevity use
Human research available	Yes for the approved indication; limited and mixed for off-label cognitive/longevity uses
Development status	Long-approved drug (first synthesized 1876; antimalarial use from 1891; methemoglobinemia indication established later)
Regulatory status	FDA-approved (marketed as Provayblue, among other formulations) for acquired methemoglobinemia; prescription-only in the US and EU; listed on the WHO Model List of Essential Medicines. Not approved for cognitive enhancement, longevity, or mitochondrial support

Technical identity

Primary name	Methylene blue (methylthioninium chloride)
Alternative names	Methylthioninium chloride; brand names including Provayblue
Peptide sequence	Not applicable — this is a small molecule, not a peptide
Amino-acid length	Not applicable — this is a small molecule, not a peptide
Molecular formula	C16H18ClN3S (chloride salt)
Molecular weight	Approximately 319.85 g/mol (chloride salt)
CAS Registry Number	61-73-4
PubChem CID	6099
Peptide class	Not applicable — synthetic phenothiazine dye
Primary biological target	Multiple — acts as an electron-cycling redox agent (reduces methemoglobin back to hemoglobin); also studied as a mitochondrial electron-transport-chain modulator and monoamine oxidase inhibitor at low doses
Developer or originator	First synthesized by Heinrich Caro, 1876; antimalarial use pioneered by Paul Ehrlich and Paul Guttmann, 1891
Development status	Long-approved drug; a more refined derivative, hydromethylthionine (LMTM/TRx0237), has been separately investigated for Alzheimer’s disease

What it is

Methylene blue (chemical name methylthioninium chloride) is a synthetic phenothiazine dye first synthesized by the German chemist Heinrich Caro in 1876. It has been called the first fully synthetic drug used in medicine. Paul Ehrlich and Paul Guttmann pioneered its use as an antimalarial in 1891, and its ability to correct methemoglobinemia (a form of oxygen-transport failure in blood) was described by Matilda Moldenhauer Brooks in the 1930s.

Today, methylene blue has a genuinely established pharmaceutical role: it is FDA-approved, sold under the brand name Provayblue among others, for treating acquired methemoglobinemia, typically given by intravenous injection when methemoglobin levels are dangerously elevated or symptoms persist despite oxygen therapy. It is also used off-label in specific clinical contexts, such as preventing neurotoxicity during certain chemotherapy regimens (ifosfamide) and, controversially, as an experimental add-on treatment explored in some psychiatric and neurodegenerative disease research.

Separately from its established medical uses, methylene blue has become popular in longevity and “biohacking” circles as a low-dose oral compound taken for claimed cognitive enhancement, mitochondrial support, and general anti-aging effects. This off-label, self-directed use is a distinct evidence category from its FDA-approved indication, uses different (typically much lower and orally administered) doses than the approved IV product, and is not supported by the same level of clinical evidence.

How does it work?

Plain-English explanation

In its FDA-approved use, methylene blue works like a chemical “reset switch” for red blood cells that have lost their ability to carry oxygen: it helps convert the iron in hemoglobin back to the form that can bind oxygen, restoring normal blood function within minutes. Separately, at much lower doses, some researchers and biohacking advocates believe methylene blue can help mitochondria (the cell’s energy-producing structures) work more efficiently by acting as an alternative electron carrier, which is the basis for the “longevity” and “cognitive enhancement” interest, though this use is far less rigorously proven than its role in treating methemoglobinemia.

Technical explanation

In methemoglobinemia, iron within hemoglobin has been oxidized from the ferrous (Fe2+) to the ferric (Fe3+) state, which cannot bind oxygen. Methylene blue is reduced by NADPH-methemoglobin reductase to leucomethylene blue, which then non-enzymatically reduces the ferric iron in methemoglobin back to the ferrous state, restoring oxygen-carrying capacity and shortening methemoglobin’s effective half-life from hours to minutes. Separately, at low concentrations, methylene blue can accept electrons directly from NADH and shuttle them to cytochrome c in the mitochondrial electron transport chain, bypassing Complex I; this “alternative electron carrier” mechanism is the basis for research into mitochondrial protection in various disease models. Methylene blue is also a reversible, nonselective monoamine oxidase inhibitor at higher doses, which underlies its serotonin syndrome risk when combined with serotonergic drugs, and it has been studied as a tau protein aggregation inhibitor in Alzheimer’s disease research (its reduced derivative, methylthioninium, was developed further as the investigational Alzheimer’s drug candidate hydromethylthionine, also known as LMTM/TRx0237).

Potential benefits and research applications

Methemoglobinemia (established, approved use)

What is being investigated: this is not investigational; it is an FDA-approved indication. How the effect works: by chemically reducing ferric iron in hemoglobin back to its oxygen-carrying ferrous state. Evidence: has been shown in extensive clinical use and is the FDA-approved standard treatment when methemoglobin exceeds 30% or symptoms persist despite oxygen. Strength: strong, established clinical evidence; this is the compound’s core validated medical use. Limitation: not relevant to longevity or cognitive-enhancement discussions; this is a distinct, approved acute-treatment indication.

Cognitive enhancement / “nootropic” use

What is being investigated: whether low-dose methylene blue improves memory, attention, or cognitive performance. How the effect might occur: proposed mitochondrial electron-transport support and antioxidant effects in brain tissue. Evidence: some small human studies and older research have explored low-dose methylene blue’s effects on memory and brain imaging measures, and animal studies have shown cognitive benefits in various models; however, dedicated, adequately powered human trials specifically validating a “nootropic” cognitive-enhancement claim at community-used doses are limited. Strength: has been reported anecdotally within biohacking communities and is being investigated in limited human and animal studies; a robust cognitive-enhancement effect at low oral doses has not been firmly established. Limitation: much of the enthusiasm around this use draws on small, older, or narrowly scoped studies rather than a large confirmatory human trial base.

Neurodegenerative disease research (Alzheimer’s tau pathology)

What is being investigated: whether methylene blue or its reduced derivative can inhibit pathological tau protein aggregation implicated in Alzheimer’s disease. How the effect might occur: by interfering with tau protein self-aggregation in laboratory and animal models. Evidence: methylene blue’s tau-aggregation-inhibiting properties led to the development of a more refined derivative (hydromethylthionine/LMTM) that was carried into registered human Phase III Alzheimer’s trials by a pharmaceutical developer; results from those later-stage trials were largely disappointing on primary endpoints. Strength: this line of research reached registered human trials, a notably higher evidence tier than most other methylene blue longevity claims, but the derivative trials did not clearly demonstrate benefit. Limitation: the pharmaceutical trials used a purpose-built derivative and dosing regimen, not the plain methylene blue sold as a longevity supplement, so results do not directly transfer to community use of the parent compound.

Mitochondrial and general longevity support

What is being investigated: whether low-dose methylene blue supports mitochondrial function broadly and contributes to healthy aging. How the effect might occur: via its alternative electron carrier activity in the mitochondrial electron transport chain, demonstrated in cell and animal studies. Evidence: cell-culture and animal studies support the mitochondrial electron-transport mechanism; direct human evidence for a general longevity or healthspan benefit from chronic low-dose methylene blue supplementation in healthy people has not been established. Strength: is being investigated for at a mechanistic and preclinical level; has not been established as a proven longevity intervention in humans. Limitation: no long-term human outcome trial for healthy-aging use exists.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

The FDA-approved dose for methemoglobinemia is 1 to 2 milligrams per kilogram of body weight given by slow intravenous injection over several minutes, which may be repeated after one hour if methemoglobin levels remain elevated (evidence category: published human clinical trial / regulatory-approved labeling). Doses above roughly 7 milligrams per kilogram carry increased risk of paradoxically worsening methemoglobinemia and other toxicity. Separately, small human studies of low-dose oral methylene blue for cognitive or memory effects have used amounts in a considerably lower range, commonly cited in the literature around 15 to 300 milligrams in single-dose or short-term study designs, though this body of research is limited in size and scope compared to the methemoglobinemia evidence base (evidence category: published human research, smaller and older studies). The Alzheimer’s disease trials using the derivative hydromethylthionine (LMTM) tested specific proprietary doses of that distinct compound, not plain methylene blue, and are not directly comparable to community-used oral methylene blue amounts.

Amounts studied in animal research

Animal studies investigating methylene blue’s mitochondrial and cognitive effects have used a range of doses, commonly cited in rodent studies in the range of roughly 1 to 4 milligrams per kilogram administered orally or by injection, though exact figures vary by study, species, and endpoint measured, and are not standardized into a single reference protocol (evidence category: published animal research).

Practitioner and community-reported protocols

Longevity and biohacking websites and forums describe low-dose oral “microdosing” protocols for methylene blue, commonly citing amounts in the range of roughly 0.5 to 4 milligrams per kilogram of body weight, or flat doses often described as 5 to 30 milligrams per day, taken orally using pharmaceutical-grade (not industrial or aquarium-grade) methylene blue diluted in water. These figures are widely repeated across biohacking blogs, longevity-clinic marketing pages, and community forums, and while some overlap loosely with doses used in small human cognitive studies, the specific community “microdosing” protocols themselves are not tied to a single identifiable clinical source and vary considerably between sites (evidence category: community/practitioner reported; origin unclear for the specific community-standard figures). Widely repeated online, but its original source could not be verified for many of the specific milligram figures promoted as an “optimal” daily biohacking dose.

Side effects, risks, and limitations

Methylene blue has real, well-documented risks that differ meaningfully by dose and context. Its most serious documented drug interaction is serotonin syndrome, a potentially life-threatening condition, when methylene blue (particularly at higher IV doses, generally cited above 5 milligrams per kilogram) is combined with serotonergic medications such as SSRIs, SNRIs, or MAOIs; this interaction risk is also a relevant concern at lower oral “biohacking” doses combined with common antidepressants, and is the reason methylene blue carries an FDA boxed warning regarding serotonin syndrome. It can cause hemolytic anemia in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic condition many people are unaware they have, and is contraindicated at the FDA-approved treatment dose in that population. Common side effects include headache, nausea, dizziness, and blue-green discoloration of urine and, at higher doses, skin. Only pharmaceutical-grade methylene blue intended for human use should be considered at all; industrial, aquarium, or laboratory-reagent-grade methylene blue is not manufactured to pharmaceutical purity standards and carries contamination risk. Long-term safety data for chronic, unsupervised, low-dose oral “biohacking” use in healthy people has not been established through dedicated long-term trials.

Regulatory and developmental status

Methylene blue is FDA-approved, marketed under the brand name Provayblue among other formulations, specifically for treating acquired methemoglobinemia. It is a prescription-only medication in the United States and the European Union, and is listed on the World Health Organization’s Model List of Essential Medicines. It is not FDA-approved for cognitive enhancement, longevity, mitochondrial support, or any other off-label use discussed in biohacking communities; those uses fall outside its approved labeling. A more refined derivative, hydromethylthionine (LMTM/TRx0237), was carried into Phase III Alzheimer’s disease trials by a separate pharmaceutical developer but did not achieve clear efficacy on primary endpoints, and is distinct from plain methylene blue as sold and used in the longevity space.

Frequently asked questions

What is methylene blue?

Methylene blue is a synthetic dye, first made in 1876, that became one of the earliest true pharmaceutical drugs. It is FDA-approved to treat methemoglobinemia, a blood disorder, and has also drawn recent interest as an off-label longevity and cognitive-enhancement compound.

How does methylene blue work?

At its FDA-approved dose, it chemically converts iron in hemoglobin back to the form that can carry oxygen. At much lower doses, it may act as an alternative electron carrier in mitochondria, which is the mechanism proposed for its longevity and cognitive-enhancement uses.

What dosage has been studied for methemoglobinemia?

The FDA-approved dose is 1 to 2 milligrams per kilogram given by slow intravenous injection, which may be repeated after one hour if needed.

What dosage circulates for longevity or cognitive use?

Biohacking and longevity websites commonly describe oral “microdosing” amounts in the range of roughly 0.5 to 4 milligrams per kilogram, or flat doses of 5 to 30 milligrams per day, but these community figures are widely repeated online without a single identifiable clinical source.

Is methylene blue FDA-approved for cognitive enhancement or longevity?

No. Its only FDA-approved indication is methemoglobinemia. Cognitive-enhancement and longevity use is off-label and not backed by the same level of clinical evidence.

What are the biggest safety risks?

Serotonin syndrome when combined with serotonergic medications (SSRIs, SNRIs, MAOIs), and hemolytic anemia risk in people with G6PD deficiency. It carries an FDA boxed warning about the serotonin syndrome risk.

Has methylene blue been studied in humans for cognitive effects?

Some small, mostly older human studies exist looking at memory and brain effects at low doses, but this is a much smaller and less rigorous evidence base than the methemoglobinemia indication.

What remains unknown?

Whether chronic low-dose oral methylene blue use produces meaningful cognitive or longevity benefits in healthy people, and the long-term safety of the specific “microdosing” protocols promoted in biohacking communities, have not been established through dedicated long-term human trials.

Bottom line

Methylene blue has a genuinely strong, decades-old evidence base and FDA approval for one specific use: treating methemoglobinemia at a defined IV dose. Its popularity in longevity and cognitive-enhancement circles rests on a much thinner evidence base, some small human studies, animal mitochondrial research, and a scientifically interesting but ultimately disappointing pharmaceutical trial of a related derivative for Alzheimer’s disease. The “microdosing” amounts circulating in biohacking communities are not validated by dedicated clinical trials at those specific doses, and the serotonin syndrome interaction risk is real and should not be dismissed regardless of how low the dose is described as being.